These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25323164)

  • 1. Women are from SATURN and men are from an ASTEROID: deciphering the REVERSAL of coronary atheroma.
    Garcia-Garcia HM; Campos CM; Serruys PW
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1023-4. PubMed ID: 25323164
    [No Abstract]   [Full Text] [Related]  

  • 2. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Saturn study].
    Fineschi M; Gaspardone A
    G Ital Cardiol (Rome); 2012; 13(7-8):469-73. PubMed ID: 22781373
    [No Abstract]   [Full Text] [Related]  

  • 4. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis.
    Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096
    [No Abstract]   [Full Text] [Related]  

  • 5. High coronary plaque load: a heavy burden.
    de Graaf MA; Jukema JW
    Eur Heart J; 2013 Nov; 34(41):3168-70. PubMed ID: 23966308
    [No Abstract]   [Full Text] [Related]  

  • 6. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin wars: emphasis on potency vs event reduction and safety?
    Lavie CJ; Milani RV; O'Keefe JH
    Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
    Koshel'skaia OA; Vinnitskaia IV; Konko TIu; Kravchenko ES; Suslova TE; Karpov RS
    Kardiologiia; 2015; 55(3):67-74. PubMed ID: 26320293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidaemia: Promising results for TA-8995 in TULIP.
    Mearns BM
    Nat Rev Cardiol; 2015 Aug; 12(8):443. PubMed ID: 26099844
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolving role of CETP inhibition: beyond HDL cholesterol.
    Ray KK; Vallejo-Vaz AJ
    Lancet; 2015 Aug; 386(9992):412-4. PubMed ID: 26047976
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
    Rawlings R; Nohria A; Liu PY; Donnelly J; Creager MA; Ganz P; Selwyn A; Liao JK
    Am J Cardiol; 2009 Feb; 103(4):437-41. PubMed ID: 19195498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
    Koksal M; Eren MA; Turan MN; Sabuncu T
    Eur J Intern Med; 2011 Jun; 22(3):249-53. PubMed ID: 21570643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
    Mori Y; Kuriyama G; Tanaka T; Tajima N
    Endocrine; 2009 Dec; 36(3):412-8. PubMed ID: 19834827
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
    Ai M; Otokozawa S; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
    Am J Cardiol; 2008 Feb; 101(3):315-8. PubMed ID: 18237592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.